Tiziana Life Sciences Ltd is a clinical-stage biotechnology company focused on developing immunotherapy-based treatments for neurodegenerative, neuroinflammatory, and lung diseases. Its current pipeline centers on candidates such as intranasal Foralumab, a fully human anti-CD3 monoclonal antibody being studied for conditions including secondary progressive multiple sclerosis, Alzheimer’s disease, amyotrophic lateral sclerosis, and other central nervous system disorders. The company is also advancing additional programs, including TZLS-501, an anti-IL-6R antibody aimed at inflammatory pathways, and Milciclib, an oncology candidate evaluated in solid tumors and related cancer indications. Tiziana Life Sciences uses alternative drug delivery approaches, including nasal, oral, and inhalation routes, to support localized immunotherapy and broaden treatment options across autoimmune, inflammatory, and cancer-related markets.
Website14/15 Conduit Street
London, W1S 2XJ
United Kingdom
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Monday the last patient has completed their final visit in the company's Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS). The randomized, double-blind,...
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has signed a Memorandum of Understanding with the King Abdullah International Medical Research Center (KAIMRC) and the Foundation for Neurologic Diseases to study its intranasal foralumab in combination with anti-CD20 therapy for multiple sclerosis...
Tiziana Life Sciences Ltd (NASDAQ:TLSA) was awarded a Buy rating with a $7 price target by BTIG, which pointed to the biotech's approach to modulating central nervous system inflammation as a potential leading treatment for neurodegenerative disease. The clinical-stage company is developing...
Investors talking about TLSA also mention
What share of all stock conversation is about TLSA?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% +0 | 0% 0 | 0% 0 |
Of the messages about TLSA that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | 33.33% -41.67 | 88.24% -2.24 | 91.21% +15.74 | 64.8% -8.97 | ||
| Bearish | 66.67% +41.67 | 11.76% +2.24 | 8.79% -15.74 | 35.2% +8.97 |
Of the messages about TLSA that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | 47.73% | 80% | 75.19% | ||
| Technical Analysis | — | 18.18% | 5.29% | 8.45% | ||
| Controversies | — | 0% | 0.59% | 2.96% | ||
| Analysts | — | 34.09% | 14.12% | 1% | ||
| Earnings | — | 0% | 0% | 8.63% | ||
| Macro | — | 0% | 0% | 3.78% |
Of the messages about TLSA, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 50% | 71.49% | 69.07% | 35.77% | ||
| Newcomers | 50% | 28.51% | 30.93% | 64.23% |